Publications by authors named "Mayla Gabriela Silva Borba"
Article Synopsis
- The study investigates the relationship between dynapenia (loss of muscle strength) and functional limitations in long COVID patients, suggesting that muscle strength may contribute to the ongoing challenges faced by these individuals.
- Out of 113 patients assessed 120 days post-severe COVID-19, 22% were found to have dynapenia, correlating with lower muscle mass, respiratory function, and exercise capacity compared to non-dynapenic peers.
- The findings indicate that measuring hand-grip strength (HGS) is an effective, cost-efficient way to gauge functional impairment in long COVID patients, potentially serving as a useful tool in clinics, particularly in less affluent areas.
Background: The novel coronavirus disease 2019 (COVID-19) presents with complex pathophysiological effects in various organ systems. Following the COVID-19, there are shifts in biomarker and cytokine equilibrium associated with altered physiological processes arising from viral damage or aggressive immunological response. We hypothesized that high daily dose methylprednisolone improved the injury biomarkers and serum cytokine profiles in COVID-19 patients.
View Article and Find Full Text PDFShort-Course of Methylprednisolone Improves Respiratory Functional Parameters After 120 Days in Hospitalized COVID-19 Patients (Metcovid Trial): A Randomized Clinical Trial.
Front Med (Lausanne)
November 2021
The use of corticosteroids may help control the cytokine storm occurring in acute respiratory failure due to the severe form of COVID-19. We evaluated the postacute effect of corticosteroids used during the acute phase, such as impairment in pulmonary function parameters, on day 120 (D120)-follow-up, in participants who survived over 28 days. This is a parallel, double-blind, randomized, placebo-controlled phase IIb clinical trial carried out between April 18 and October 9, 2020, conducted in hospitalized patients with clinical-radiological suspicion of COVID-19, aged 18 years or older, with SpO ≤ 94% on room air or requiring supplementary oxygen, or under invasive mechanical ventilation (IMV) in a referral center in Manaus, Western Brazilian Amazon.
View Article and Find Full Text PDFArticle Synopsis
- SARS-CoV-2 uses the ACE2 receptor to infect various human tissues, with higher levels of ACE2 observed in patients with comorbidities linked to severe COVID-19.
- Patients with Barrett's esophagus (BE) exhibit increased ACE2 expression in BE tissues, potentially due to the lower pH associated with this condition.
- The study indicates that lower pH increases ACE2 expression and viral load in human monocytes and that prior use of proton pump inhibitors may significantly elevate the risk of death from COVID-19.
Although high mortality has been reported in many COVID-19 studies, very limited postmortem information from complete autopsies is available. We report the findings in the adrenal glands in 28 autopsies with confirmed SARS-CoV-2 infection. Microscopic lesions were identified in the adrenal glands in 12/28 patients (46%).
View Article and Find Full Text PDFMethylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial.
Clin Infect Dis
May 2021
Background: Steroid use for coronavirus disease 2019 (COVID-19) is based on the possible role of these drugs in mitigating the inflammatory response, mainly in the lungs, triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to evaluate the efficacy of methylprednisolone (MP) among hospitalized patients with suspected COVID-19.
Methods: A parallel, double-blind, placebo-controlled, randomized, Phase IIb clinical trial was performed with hospitalized patients aged ≥18 years with clinical, epidemiological, and/or radiological suspected COVID-19 at a tertiary care facility in Manaus, Brazil.
We report the case of a 15-year-old male patient presenting frontal headaches with retro-orbital pain accompanied by fever evolving to weakness and pain of the lower limbs, which ascended to upper limbs. A COVID-19 rapid test (IgG and IgM) and nasopharyngeal swab polymerase chain reaction (PCR) was positive for SARS-CoV-2. The blood tests, cerebral spinal fluid (CSF) analysis and CSF aerobic culture revealed no abnormalities.
View Article and Find Full Text PDFEffect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
JAMA Netw Open
April 2020
Importance: There is no specific antiviral therapy recommended for coronavirus disease 2019 (COVID-19). In vitro studies indicate that the antiviral effect of chloroquine diphosphate (CQ) requires a high concentration of the drug.
Objective: To evaluate the safety and efficacy of 2 CQ dosages in patients with severe COVID-19.